Objective To systematically evaluate the intervention effect of Chinese medicine on autoimmune myasthenia gravis animals. Methods CNKI

Wanfang Database

Chongqing VIP Chinese Science and Technology Journal Database

China Biomedical Literature Database

Pub Med

Cochrane Library and Embase were selected to screen Chinese medicine for the treatment of autoimmune myasthenia gravis animals

and data extraction tables were formulated and the data were extracted. Risk assessment of the methodological bias of the included literature was performed by using the SYRCLE Animal Test Bias Risk Assessment Tool and the meta-analysis of outcome indicators [including Lennon score and serum acetylcholine receptor antibody（AchR-Ab）

interleukin 4（IL-4）

interleukin-6（IL-6）

γ-interferon（IFN-γ）

transforming growth factor β（TGF-β）

and tumor necrosis factor α（TNF-α） ]was conducted with Rev Man 5. 3 software. Results A total of 18 studies were included in the study. The subkects were Lewis rats or SD rats or C57 BL/6 mice

and all the studies were randomized controlled trials. But the risk of bias was higher. Meta-analysis showed that the Chinese medicine group could improve the model animal Lennon score[SMD =-1. 75

95% CI（-2. 54

-0. 96）

P < 0. 0001]

reduce serum AchR-Ab [SMD =-5. 60

95% CI（-7. 31

-3. 88）

P < 0. 0001) ]

IL-4 [SMD =-2. 96

95% CI（-4. 69

-1. 23）

P = 0. 0008]

IL-6[SMD =-3. 65

95% CI（-5. 01

-2. 29）

P < 0. 0001]

IFN-γ [SMD =-3. 73

95% CI（-5. 43

-2. 03）

P < 0. 0001]

TNF-α [SMD =-2. 19

95% CI（-3. 71

0. 66）

P = 0. 007] content

increased serum TGF-β content [SMD = 4. 43

95% CI（1. 84

7. 01）

P = 0. 0008]. Conclusion Chinese medicine can regulate the changes of immune-related cytokines and improve symptoms of autoimmune myasthenia gravis animals.